GLYT1 Inhibition Reduces Schizophrenia-like Symptoms Produced by Ketamine

被引：0
|
作者：
Driesen, Naomi R. [1 ,2 ]
Ranganathan, Mohini [1 ,3 ]
DeMartinis, Nicholas [4 ]
Bloch, Michael [1 ]
Morgan, Peter T. [1 ]
Gueorguieva, Raitza [1 ,5 ]
Ahn, Kyungheup [1 ,3 ]
D'Souza, Deepak C. [1 ,3 ]
Krystal, John H. [1 ,3 ]
机构：
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] VA Connecticut Hlth Care Syst, Psychol, West Haven, CT USA
[3] VA Connecticut Hlth Care Syst, Psychiat, West Haven, CT USA
[4] Pfizer, Neurosci, Cambridge, MA USA
[5] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA
来源：
BIOLOGICAL PSYCHIATRY | 2015年 / 77卷 / 09期
关键词：
NMDA Receptor; Ketamine; Positive Symptoms; GlyT1; Inhibitor; Schizophrenia;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
561
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness
    Dolder, Christian
    EVIDENCE-BASED MENTAL HEALTH, 2008, 11 (04) : 114 - 114
  • [2] DEVELOPMENT OF GLYT1 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
    Schmidt, Christopher
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 114 - 114
  • [3] Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
    Driesen, N. R.
    McCarthy, G.
    Bhagwagar, Z.
    Bloch, M.
    Calhoun, V.
    D'Souza, D. C.
    Gueorguieva, R.
    He, G.
    Ramachandran, R.
    Suckow, R. F.
    Anticevic, A.
    Morgan, P. T.
    Krystal, J. H.
    MOLECULAR PSYCHIATRY, 2013, 18 (11) : 1199 - 1204
  • [4] Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
    N R Driesen
    G McCarthy
    Z Bhagwagar
    M Bloch
    V Calhoun
    D C D'Souza
    R Gueorguieva
    G He
    R Ramachandran
    R F Suckow
    A Anticevic
    P T Morgan
    J H Krystal
    Molecular Psychiatry, 2013, 18 : 1199 - 1204
  • [5] Biochemical effects of GlyT1 inhibition by NFPS
    Harms, JF
    Lebel, LA
    Lowe, JA
    Schmidt, CJ
    MONITORING MOLECULES IN NEUROSCIENCE, 2001, : 291 - 292
  • [6] EXPERIMENTAL SCHIZOPHRENIA-LIKE SYMPTOMS
    RINKEL, M
    DESHON, HJ
    HYDE, RW
    SOLOMON, HC
    AMERICAN JOURNAL OF PSYCHIATRY, 1952, 108 (08): : 572 - 578
  • [7] Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)
    Chue, Pierre
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (07) : 1311 - 1320
  • [8] GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats
    Liu, Chang-Ning
    Pettersen, Betty
    Seitis, Gary
    Osgood, Sarah
    Somps, Chris
    CUTANEOUS AND OCULAR TOXICOLOGY, 2014, 33 (03) : 206 - 211
  • [9] A new approach in the use of GlyT1 inhibitors for treatment of schizophrenia
    Szabo, G.
    FEBS JOURNAL, 2009, 276 : 346 - 346
  • [10] Ascorbic acid supplementation attenuates schizophrenia-like symptoms in an animal model induced by ketamine
    Supp, Angelo D.
    Avila Jr, Silvio
    Mastella, Gustavo A.
    Damasio, Louyse
    de Oliveira, Isabela H.
    Godoi, Amanda K.
    Michels, Alander
    Schuck, Patricia F.
    Zugno, Alexandra, I
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2021, 81 (01) : 26 - 36
12345